Across the cannabis market, multiple cannabinoids have seen rapid growth. Considering the differing effects between specific cannabinoids, it is critical to assess effects on an individual level. Hexahydrocannabinol (HHC) is one intoxicating cannabinoid that became more accessible due to regulatory shifts. The purpose of the current study was to provide descriptive data regarding HHC use patterns and perceived effects within a sample of participants who endorsed recent HHC use.
Methods:
One hundred nine individuals self-reported use of an HHC-cannabis product at least once within 6 months and completed an HHC use questionnaire via Prolific, an online crowdsourcing platform.
Results:
Findings suggest recent HHC users are using HHC relatively frequently (∼10 days during the past month) for various indications, including anxiety and pain. HHC was perceived to yield more good than bad effects, including relaxation and euphoria. Approximately 17% of the sample reported adverse effects, and ∼20% of those who stopped using HHC experienced some withdrawal symptoms. Few meaningful sex differences in subjective effect ratings were observed.
Discussion:
The current study provides critical preliminary data about consumer use patterns and perceived effects related to HHC. Such data are needed to further research on the potential therapeutic as well as detrimental effects of HHC and to better inform the consumers, health professionals, and regulators about a cannabinoid that is widely available the market.
SchulenbergJ, JohnstonL, O'MalleyP, et al.Monitoring the Future National Survey Results on Drug Use, 1975–2019: Volume II, College Students and Adults Ages 19–60. University of Michigan, Institute for Social Research: MI, USA; 2020.
3.
WysotaCN, LeD, ClausenME, et al.Young adults' knowledge, perceptions and use of cannabidiol products: A mixed-methods study. Health Educ Res, 2022; 37(6):379–392; doi: 10.1093/her/cyac030
4.
BergeriaCL, StricklandJC, SpindleTR, et al.A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol. Exp Clin Psychopharmol, 2023; 31(2):312–317; doi: 10.1037/pha0000565
5.
ConnorJP, StjepanovićD, Le FollB, et al.Cannabis use and cannabis use disorder. Nat Rev Dis Primers, 2021; 7(1):16.
6.
MaccarroneM, MaldonadoR, CasasM, et al.Cannabinoids therapeutic use: What is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?. Expert Rev Clin Pharmacol, 2017; 10(4):443–455; doi: 10.1080/17512433.2017.1292849
7.
MillarSA, StoneNL, BellmanZD, et al.A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol, 2019; 85(9):1888–1900; doi: 10.1111/bcp.14038
8.
Bonn-MillerMO, SisleyS, RiggsP, et al.The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. PLoS One, 2021; 16(3):e0246990; doi: 10.1371/journal.pone.0246990
9.
FerrettiML, VandreyR, IronsJG, et al.Likelihood of positive urine screens of THC-COOH after daily use of full-spectrum hemp extracts varies as a function of screening criterion used. Ther Drug Monit, 2023; 45(1):126–127; doi: 10.1097/FTD.0000000000001032
10.
GournayLR, PetryJ, BilskyS, et al.Cannabidiol reduces nicotine withdrawal severity and state anxiety during an acute e-cigarette abstinence period: A novel, open-label study. Cannabis Cannabinoid Res, 2023. [Epub ahead of print]; doi: 10.1089/can.2022.0317
11.
Leen-FeldnerEW, BynionT-M, EglitGML, et al.A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on fear elicited by a 10% carbon dioxide-enriched air breathing challenge. Psychopharmacology (Berl), 2022. [Epub ahead of print]; doi: 10.1007/s00213-022-06258-7
12.
StanleyTB, FerrettiML, Bonn-MillerMO, et al.A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on experiences of test anxiety among college students. Cannabis Cannabinoid Res, 2022. [Epub ahead of print]; doi: 10.1089/can.2022.0062
RussoEB, CuttlerC, CooperZD, et al.Survey of patients employing cannabigerol-predominant cannabis preparations: Perceived medical effects, adverse events, and withdrawal symptoms. Cannabis Cannabinoid Res, 2022; 7(5):706–716; doi: 10.1089/can.2021.0058
15.
PellicaneMJ, QuinnME, BeanCAL, et al.Delta-8- and delta-9-thc use frequency, use motives, and mental health outcomes. J Psychoactive Drugs, 2023; 1–7. [Epub ahead of print]; doi: 10.1080/02791072.2023.2200211
16.
CasatiS, RotaP, BergamaschiRF, et al.Hexahydrocannabinol on the light cannabis market: The latest “New” entry. Cannabis Cannabinoid Res, 2022. [Epub ahead of print]; doi: 10.1089/can.2022.0253
17.
RussoF, VandelliMA, BiaginiG, et al.Synthesis and pharmacological activity of the epimers of hexahydrocannabinol (HHC). Sci Rep, 2023; 13(1):11061; doi: 10.1038/s41598-023-38188-5
18.
NikasSP, AlapafujaSO, PapanastasiouI, et al.Novel 1′,1′-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. J Med Chem, 2010; 53(19):6996–7010; doi: 10.1021/jm100641g
19.
UjváryI.Hexahydrocannabinol and closely related semi-synthetic cannabinoids: A comprehensive review. Drug Test Anal, 2023. [Epub ahead of print]; doi: 10.1002/dta.3519
20.
WheelerM, MertenJW, GordonBT, et al.CBD (Cannabidiol) product attitudes, knowledge, and use among young adults. Subst Use Misuse, 2020; 55(7):1138–1145; doi: 10.1080/10826084.2020.1729201
21.
CooperZD, HaneyM. Investigation of sex-dependent effects of cannabis in daily cannabis smokers. Drug Alcohol Depend, 2014; 136:85–91; doi: 10.1016/j.drugalcdep.2013.12.013
22.
LakeS, HaneyM, CooperZD. Sex differences in the subjective and reinforcing effects of smoked cannabis. Addict Biol, 2023; 28(7):e13301; doi: 10.1111/adb.13301
23.
MacNairL, EglitGML, MosesovaI, et al.Sex differences in the safety and subjective effects of two oral δ9-tetrahydrocannabinol-containing cannabis products over multiple doses among healthy adults. Cannabis Cannabinoid Res, 2023. [Epub ahead of print]; doi: 10.1089/can.2022.0340
24.
ShollerDJ, StricklandJC, SpindleTR, et al.Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addict Biol, 2021; 26(4):e12968; doi: 10.1111/adb.12968
25.
MillarSA, StoneNL, YatesAS, et al.A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol, 2018; 9:1365; doi: 10.3389/fphar.2018.01365
26.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed., text rev. Amer Psychiatric Pub Inc: Virginia, USA; 2022.
27.
FerrettiML.A Survey Study of Individuals Using Hexahydrocannabinol-Predominant Cannabis Products. Open Science Framework (OSF), 2023.
28.
AmrheinV, GreenlandS, McShaneB. Scientists rise up against statistical significance. Nature, 2019; 567(7748):305–307; doi: 10.1038/d41586-019-00857-9
CrippaJA, ZuardiAW, Martín-SantosR, et al.Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol Clin Exp, 2009; 24(7):515–523; doi: 10.1002/hup.1048
31.
GedinF, BloméS, PonténM, et al.Placebo response and media attention in randomized clinical trials assessing cannabis-based therapies for pain: A systematic review and meta-analysis. JAMA Netw Open, 2022; 5(11):e2243848; doi: 10.1001/jamanetworkopen.2022.43848
32.
SpinellaTC, StewartSH, NauglerJ, et al.Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: A randomized crossover study. Psychopharmacology (Berl), 2021; 238(7):1965–1977; doi: 10.1007/s00213-021-05823-w
33.
PoyatosL, Pérez-AcevedoAP, PapaseitE, et al.Oral administration of cannabis and δ-9-tetrahydrocannabinol (THC) preparations: A systematic review. Medicina (Kaunas), 2020; 56(6):309; doi: 10.3390/medicina56060309
34.
SpindleTR, ConeEJ, GoffiE, et al.Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug Alcohol Depend, 2020; 211:107937; doi: 10.1016/j.drugalcdep.2020.107937
35.
LaFranceEM, StueberA, GlodoskyNC, et al.Overbaked: Assessing and predicting acute adverse reactions to Cannabis. J Cannabis Res, 2020; 2(1):3; doi: 10.1186/s42238-019-0013-x
36.
LeasEC, HaratiRM, SatybaldiyevaN, et al.Self-reported adverse events associated with Δ8-tetrahydrocannabinol (Delta-8-THC) use. J Cannabis Res, 2023; 5(1):15; doi: 10.1186/s42238-023-00191-y
37.
CorroonJ, PhillipsJA. A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res, 2018; 3(1):152–161; doi: 10.1089/can.2018.0006
38.
BudneyAJ, HughesJR, MooreBA, et al.Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry, 2004; 161(11):1967–1977; doi: 10.1176/appi.ajp.161.11.1967
Walukevich-DienstK, MorrisPE, TuckerRP, et al.Development and initial psychometric properties of the Cannabidiol Outcome Expectancies Questionnaire (CBD-OEQ). Psychol Assess, 2022; 34(7):643–659; doi: 10.1037/pas0001128
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
